This dose falls within the effective clinical range while allowing room to increase if response is minimal
This can be more convenient for both patients and healthcare providers
Discontinue if: Significant adverse reactions occur, you achieve body composition goals, no response after 8-12 weeks at optimal dosing, medical contraindications develop, or pregnancy occurs
Known and theoretical safety concerns include: Retatrutide (and the GLP-1 receptor agonist class): Nausea, vomiting, diarrhoea, and reduced appetite are the most commonly reported side effects
Injections are very effective at raising blood levels of vitamin B12 and preventing or reversing a B12 deficiency
The Phase IIb oral trial administered doses well above the typical subcutaneous research dose for 24 weeks without serious adverse events attributable to the peptide [6]